Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Angeles Investment Advisors LLC

Angeles Investment Advisors LLC grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 14.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,354 shares of the medical research company’s stock after buying an additional 170 shares during the period. Angeles Investment Advisors LLC’s holdings in Bio-Rad Laboratories were worth $773,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Norges Bank purchased a new stake in Bio-Rad Laboratories in the 4th quarter valued at $119,609,000. UBS Asset Management Americas Inc. raised its position in Bio-Rad Laboratories by 30.4% during the 4th quarter. UBS Asset Management Americas Inc. now owns 503,557 shares of the medical research company’s stock worth $293,544,000 after buying an additional 117,413 shares during the last quarter. Alliancebernstein L.P. raised its position in Bio-Rad Laboratories by 20.4% during the 1st quarter. Alliancebernstein L.P. now owns 466,361 shares of the medical research company’s stock worth $266,371,000 after buying an additional 79,174 shares during the last quarter. Brown Advisory Inc. raised its position in Bio-Rad Laboratories by 11.9% during the 1st quarter. Brown Advisory Inc. now owns 532,187 shares of the medical research company’s stock worth $303,970,000 after buying an additional 56,515 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Bio-Rad Laboratories by 18.8% during the 1st quarter. Acadian Asset Management LLC now owns 288,999 shares of the medical research company’s stock worth $165,068,000 after purchasing an additional 45,687 shares during the period. Institutional investors and hedge funds own 65.07% of the company’s stock.

NYSE BIO traded up $9.86 during trading hours on Thursday, reaching $672.91. The company’s stock had a trading volume of 244 shares, compared to its average volume of 101,837. The company has a market cap of $20.03 billion, a PE ratio of 48.33 and a beta of 0.83. Bio-Rad Laboratories, Inc. has a fifty-two week low of $472.84 and a fifty-two week high of $689.00. The business’s 50-day moving average price is $623.87.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, April 29th. The medical research company reported $5.21 EPS for the quarter, beating the Zacks’ consensus estimate of $2.50 by $2.71. Bio-Rad Laboratories had a net margin of 151.73% and a return on equity of 4.55%. The firm had revenue of $726.80 million for the quarter, compared to analysts’ expectations of $661.00 million. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 12.07 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Story: What is the Euro STOXX 50 Index?

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.